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Aim: The genetic mechanisms of resistance to chemotherapy in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 
(B-CLL/SLL) are not clear. We aimed to determine the peculiarities of abnormal karyotype formation in bone marrow (BM) cells 
and peripheral blood (PB) blast transformed B-cells in relapse of B-CLL/SLL. Materials and Methods: Cytogenetic GTG banding 
technique and molecular cytogenetic in interphase cells (i-FISH) studies of BM cells and PB blast transformed B-lymphocytes were 
performed in 14 patients (10 males and 4 females) with B-CLL/SLL. Results: The results of karyotyping BM and PB cells revealed 
the heterogeneity of cytogenetic abnormalities in combined single nosological group of B-CLL/SLL. In PB B-cells, chromosome 
abnormalities related to a poor prognosis group were registered 2.5 times more often than in BM cells. Additional near tetraploid 
clones that occurred in 57.1% cases were the peculiar feature of BM cell karyotypes. Chromosomal rearrangements characteristic 
of the group of adverse cytogenetic prognosis were revealed in all cases from which in 2 cases by karyotyping BM cells, in 6 cases 
in PB B-cells and in 8 cases by the i-FISH method in BM cells, i.e. their detection frequency was 3 times higher in PB B-cells and 
4 times higher when analyzing by i-FISH in BM cells. Conclusions: Mismatch in abnormal karyotypes in BM and PB B-cells by the 
presence of quantitative and structural chromosomal rearrangements may be indicative of simultaneous and independent processes 
of abnormal clone formation in the lymph nodes and BM hematopoietic cells. Accumulation the information about previously unidenti-
fied chromosomal rearrangements in relapse of the disease may help to understand the ways of resistance formation to chemotherapy.
Key Words: B-cell chronic lymphocytic leukemia, lymphoma of small lymphocytes, relapse, bone marrow, blast transformed B-cells, 
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B-cell chronic lymphocytic leukemia (B-CLL) is the 
most common type of leukemia among the population 
of Europe and North America countries, and makes 
up approximately 30.0% of all neoplasia of hemato-
poietic and lymphoid tissues. In Ukraine today, about 
11,000 people are diagnosed and registered with 
CLL. The WHO classification of tumors of hemato-
poietic and lymphoid tissues (2016) combines B-CLL 
with small lymphocytic lymphoma (SLL) considered 
as a single nosology form [1]. Cytomorphological 
identity characteristics, immunophenotype and the 
results of molecular genetic analysis serves as a basis 
for such unified B-CLL/SLL entity. Both diseases have 
a clonal origin from B-cells while in SLL, substrate 
cells are not detected in the peripheral blood (PB) [2]. 
In B-CLL, primary genetic rearrangements may occur 
in B-cells of bone marrow (BM). Further repeated anti-
genic stimulation leads to the accumulation of additional 
genetic rearrangements resulting in leukemia develop-
ment. Evaluation of genetic abnormalities, in particular 
cytogenetic, conducted at diagnosis, is necessary for 
better understanding of the biological characteristics 
of the tumor and the prognosis, being advantageous 
for the stratification of patients in clinical risk groups [3].
Recently, for evaluation of genetic rearrangements, 
the fluorescence in situ hybridization (FISH) of inter-
phase nuclei FISH (i-FISH) has been commonly used, 
i.e. analysis of chromosomal rearrangements is car-
ried out in non-dividing cells. However, this method 
has limitations since only those genome regions are 
identified for which FISH probes are available.
Comparison of chromosomal abnormalities with the 
disease peculiarities and the response to chemotherapy 
allowed distinguishing between three groups of cytoge-
netic prognosis. To the group with favorable prognosis, 
the patients with cytogenetically normal karyotype and 
del(13q) detectable by i-FISH are included. The group 
with adverse prognosis includes the patients who have 
been registered for following changes: del(11q) with the 
loss of ATM gene and del(17p) with the loss of a tumor 
suppressor gene TP53. Malignant cells, which carry 
these abnorma lities, are characterized by resistance 
to conventional chemotherapy with purine analogs and 
alkylating agents. In addition, the patients with del(6)
(q21-23) are included in this group. Trisomy 12 as well 
as the abnormalities not listed in the previous two groups 
constitute a group of intermediate prognosis [4–6].
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The complexity of standard cytogenetic study 
of metaphase chromosomes in BM cells by G-banding 
is associated with low proliferative activity of substrate 
cells and their accumulation in G0/G1 phase of cell 
cycle. For obtaining a population of dividing cells, the 
stimulation by B-cell mitogens such as pokeweed 
mitogen (PWM), 12-O-tetradecanoyl-phorbol-13-ace-
tate (TPA), lipopolysaccharides are traditionally used. 
However, the frequency of abnormal clones in such 
blast transformed B-lymphocytes makes up only 40–
50% [7–9]. To improve the effectiveness of cytogenetic 
studies, the attempts were made to use other stimulators 
of the cell cycle. Among the new mitogens, the CpG-
oligodeoxynucleotide DSP30 (CpG-ODN) [10] is used. 
Thus, detection of chromosomal abnormalities increases 
to 80% of cases. Moreover, the rearrangements have 
been registered that had not been described previously.
Therefore, we aimed to determine the patterns 
of abnormal karyotypes in BM cells and PB blast 
transformed B-lymphocytes in relapse of B-CLL/SLL.
MATERIALS AND METHODS
Patients. Cytogenetic and molecular cytogenetic 
studies of BM cells and blast transformed B-lymphocytes 
were performed in 14 patients (10 males and 4 females) 
with B-CLL/SLL. The average age in the group was 
53.3 years (range 40 to 65 years). The leukocyte count 
in patients examined was recorded within 7.4–78.4•109/l, 
hemoglobin — 121.0–155.0 g/l, thrombocytes — 
106.0–294.0•109/l, the lymphocyte count in PB ranged 
from 69.0 to 98.0%. The patients gave written informed 
consent for the publication of their data analyses.
Cytogenetic studies. Metaphase chromosome 
of BM cells were prepared according to the conventional 
method [11] after 24 h culture in RPMI 1640 medium supple-
mented with 20% fetal bovine serum followed by G-bands 
staining (GTG technique). Metaphase chromosomes 
of PB blast transformed B-lymphocytes were prepared 
after 72 h of culture in RPMI 1640 medium containing 10% 
fetal bovine serum, 3.6 mg/ml gentamicin and CpG-ODN 
mitogen at a final concentration of 2.5 µg/ml [12].
Identified chromosomal abnormalities were de-
scribed according to the International nomenclature 
of human chromosomes ISCN 2013 [13]. Only clonal 
chromosomal abnormalities were taken into account 
in the study. The karyotype was considered as normal 
when no less than 20 analyzed and 10 karyotyped meta-
phase plates showed no chromosomal abnormalities.
Table. Comparison of results of cytogenetic and molecular cytogenetic studies of BM cells and PB blast transformed B-lymphocytes in relapse of B-CLL  
Group Method № Bone marrow cells B-lymphocytes of peripheral blood
Group 1 GTG 1 46,XY[22]/4n±[3] 46,XY,del(6)(q16)[20]
i-FISH nuc ish(ATM,p53)x2[200],(D13S319,13q34,CEP12)x2[300]
GTG 2 46,XY[17]/4n±[3] 46,XY,t(2;18)(p24;q12),del(11)(q13)[20]
i-FISH nuc ish(ATMx1)[78/100], (p53x1)[26/100],
(D13S319,13q34,CEP12)x2[300]
GTG 3 46,XY[23]/4n±[2] 46,XY,del(13)(q12q14)[10]/46,XY[10]
i-FISH nuc ish(ATMx2)[100],(p53x1)[16/100],
(D13S319x1)[25/100],(13q34,CEP12)x2[200]
GTG 4 46,XY[20] 46,XY,-8,+12,der(14)[9]/46,XY[11]
i-FISH nuc ish(ATM,p53)x2[200],(D13S319,13q34)x2[200],
(CEP12x1,CEP12dimx1)[90/100]
Group 2 GTG 5 46,XX,del(13)(q12q14)[8]/46,XX[16] 46,XX[20]
i-FISH nuc ish(ATM,p53)x2[200],(D13S319x1)[24/100],
(13q34,CEP12)x2[200]
GTG 6 46,XY, del(13)(q12q14)[14]/46,XY[10] 46,XY[20]
i-FISH nuc ish(ATMx2)[100],(p53x1)[13/100],
(D13S319x1)[73/100],(13q34,CEP12)x2[200]
GTG 7 47,XY,+21[7]/46,XY,+t(10;16)(q25;q13),
-der(16)t(10;16)(q25;q13)[2]/4n±[3]/46,XY[11]
46,XY[20]
i-FISH nuc ish(ATMx2)[100],(p53x1)[13/100],
(D13S319,13q34,CEP12)x2[300]
GTG 8 46,XX,del(13)(q12q14)[5]/4n±[3]/46,XX[12] 46,XX[20]
i-FISH nuc ish(ATMx2)[100],(p53x1)[10/100],
(D13S319,13q34,CEP12)x2[300]
GTG 9 45,XY,t(20;17)(q13.?;p11)[2]/4n±[4]/46,XY[24] 46,XY[20]
i-FISH nuc ish(ATM,p53)x2[200],
(D13S319,13q34,CEP12)x2[300]
Group 3 GTG 10 46,XX,del(17)(p12)[3]/4n±[3]/46,XX[14] 46,XX,del(17)(p12)[7]/46,XX[13]
i-FISH nuc ish(ATMx2)[100],(p53x1)[84/100],
(D13S319x1)[39/100],(13q34x1)[15/100],(CEP12x2)[100]
GTG 11 46,XX,der(2),del(11)(p13q23)[11]/4n±[2]/46,XX[7] 46,XX,der(2),del(11)(p13q23)[20]
i-FISH nuc ish(ATMx1)[92/100],(p53x1)
[10/100],(D13S319,13q34,CEP12)x2[300]
GTG 12 47,XY,+12[6]/46,XY[14] 49,XY,+12,+18,+19[20]
i-FISH nuc ish(ATM,p53)x2[100],(D13S319x1)[40/100],
(13q34x2)[100],(CEP12x3)[43/100]
GTG 13 47,XY,+20[2]/46,XY[8] 46~47,XY,+del(6)(q24)[3]/46,XY[2]
i-FISH nuc ish(ATMx1)[42/100],(p53x1)[34/100],
(D13S319x1)[28/100],(13q34x1)[10/100],(CEP12x2)[100]
GTG 14 45,X,-Y[4]/46,XY,der(13)[3]/46,XY[18] 46,XY,dup(3)(q21q26),del(11)(q23),
del(13)(q14)[20]
i-FISH nuc ish(ATMx1)[43/100],
(p53x1)[15/100],(D13S319x1)[35/100],
(13q34,CEP12)x2[200]
Note: GTG – karyotyping by GTG banding technique; і-FISH – molecular cytogenetic assay
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i-FISH was performed after 24-h or 72-h culture. For 
this purpose, two sets were used: Vysis LSI p53 (locus 
specific probe for TP53 gene detection located in the disk 
17р13.1), LSI ATM (probe for registration ATM gene lo-
cated in the disk 11q22.3) and LSI D13S319 (disc 13q14), 
LSI 13q34, CEP12 (centromeric region of chromosome 
12) (Abbott, USA). The error of method was 8.0%.
RESULTS ANS DISCUSSION
The results of BM cells and PB blast transformed 
B-lymphocytes karyotyping were divided into three 
groups according to the clone structure. For all cases, 
in parallel, the molecular cytogenetic studies were car-
ried out in i-FISH (Table). A distinctive feature of a half 
of BM cell karyotypes was the presence of additional 
near tetraploid clone (50%) (No. 1–3, 8–11). Formation 
of abnormal clones both in BM (Fig. 1) and PB (Fig. 2) was 
due to quantitative (monosomy, trisomy, marker chro-
mosomes) and structural chromosomal rearrangements 
(deletions, translocations, derivative chromosomes).
Four cases were related to the first group, where nor-
mal (N) (No. 4) and the mosaic karyotypes (normal and 
near teraploid clones — N/4n±) (No. 1–3) were registered 
in BM cells. In addition, microdeletions of ATM genes, 
TP53 (No. 2) and 13q14, TP53 (No. 3) were identified in this 
group by i-FISH method that was confirmed by karyo-
typing PB cells of these patients, namely: del(11)(q13) 
(No. 2) and del(13)(q12q14) (No. 3). At the same time, 
in PB B-cells, the karyotypes were represented by the 
pseudodiploid clones formed as a result of deletions — 
del(6)(q16) (№ 1), del(11)(q13) (No. 2), del(13)(q12q14) 
(No. 3), the pre sence of the derivative chromosome 
14 (No. 4), and unba lanced quantitative abnormalities — 
monosomy 8 and trisomy 12 (No. 4). In 2 cases (No. 3, 4) 
in PB, the mosaic karyotype was registered, wherein the 
se cond clone was represented by cytogenetically normal 
karyotype, possibly due to the presence of normal lym-
phocytes. Interesting results were obtained in cases No. 
1 and 4. On the one hand, the study of BM showed the 
cytogenetically normal karyotype and absence of deletion 
in the regions carrying the tumor suppressor genes. On the 
other hand, the presence of chromosomal abnormalities 
in PB in these patients may indicate the origin of these 
abnormal clones outside the BM and is likely to evidence 
in favor of SLL with the leukemization.
In the second group, the reverse situation was ob-
served, namely, a normal karyotype was revealed in B-cells 
of PB while in BM cells almost all abnormal clones were 
pseudodiploid. Thus, in 3 cases the abnormal clone was 
formed by an unbalanced structural rearrangement, the 
interstitial deletion del(13)(q12q14) (No. 5, 6, 8); in 2 other 
cases, trisomy 21 and unbalanced translocation, t(10;16)
(q25;q13) (No. 7) and t(20;17)(q13;p11.?) (No. 9) were 
detected. The absence of abnormal karyotypes in B-cells 
of PB and their presence in BM cells may indicate that the 
BM is the source of the abnormal clone formation.
In the third group, the clonal abnormalities were 
revealed both in BM cells and B-cells of PB. Thus, 
in the first two cases, the abnormal clones in BM as well 
as in PB consisted of identical structural chromosomal 
rearrangements: del(17)(p12) (No. 10) and der(2), del(11)
(p13q23) (No. 11). In all cases, the mosaic karyotype with 
presence of cytogenetically normal clone was observed 
in BM cells, while in PB the presence of cytogenetically 
normal clone was detected only in 2 cases out of 5 (No. 10, 
13), which may indicate the relative safety of the cellular 
pool of BM hematopoietic cells in the patients. In the 
case No. 12, the BM cells and PB B-cells shared the tri-
somy of chromosome 12, which is typical for B-CLL, and 
is re gistered with the karyotyping in 10–15% cases, and 
in 30% — by FISH [14]. However, in cases No. 12–14, the 
numerical and structural clonal abnormalities in BM and 
PB did not coincide. Such diversity appears to be due 
to the existence of additional mechanisms for the forma-
tion of the populations of malignant cells in B-CLL/SLL also 
taking into account the role of microenvironmental factors.
In general, the chromosomal abnormalities in BM cells 
in a group with an adverse cytogenetic prognosis were 
detected in 2 cases by karyotyping (No. 10, 11) and 
in 9 cases using i-FISH (No. 2, 3, 6, 7, 8, 10, 11, 13 and 
14), two of which were identified in the cytogenetically 
normal karyotypes. Abnorma lities related to the group 
of a favorable prognosis were detected in 7 cases 
(No. 1–6, 8) on karyotyping results, wherein results 
of FISH for 4 patients (No. 2, 3, 6, 8) ranked to a group 
of poor prognosis mainly due to the presence of del(17). 
8 patients (No. 5–9, 12–14) after karyotyping were as-
signed to the group of intermediate prognosis, 5 of them 
Fig. 2. Structural chromosomal rearrangements of PB blast 
transformed cells in relapse of B-CLL/SLL
Fig. 1. Structural chromosomal rearrangements of BM cells 
in relapse of B-CLL/SLL
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being in the group of poor prognosis according to the 
results of FISH analysis (No. 6, 7, 8, 13, 14).
In PB B-cells, abnormalities ranked to a poor progno-
sis group by karyotyping results were reported in 6 cases 
(No. 1, 2, 10, 11, 13, 14). The group attri buted to the favor-
able cytogenetical prognosis included 6 cases (No. 3, 5–9). 
The chromosomal aberrations belonging to the group of in-
termediate prognosis (No. 4, 12) were revealed in 2 cases.
Thus, the results of karyotyping BM and PB cells 
revealed the heterogeneity of cytogenetic abnorma-
lities in a single nosological group B-CLL/SLL. Based 
on karyotyping, in PB B-cells chromosome abnorma-
lities related to a poor prognosis group were registered 
2.5 times more often than in BM cells. However, results 
of FISH analysis in BM cells allowed us to increase the 
number of patients with a poor prognosis that occurs 
mainly due to the presence of del(11) and del(17), i.e. as-
sociated with a loss of tumor suppressor genes [15–20].
Therefore, the results of karyotyping have shown hetero-
geneity of cytogenetic abnormalities by karyotype structure, 
ploidy, numerical and structural chromosome rearrange-
ments in a single nosological group of B-CLL/SLL. Additional 
near-tetraploid clones that occurred in 57.1% cases were 
the peculiar feature of the BM cell karyotypes. Chromo-
somal rearrangements characteristic of the group of adverse 
cytogenetic prognosis were revealed in all cases from which 
2 cases — by karyotyping of BM cells, 6 — in PB B-cells and 
8 — by the i-FISH method in BM cells, i.e. their detection 
frequency was 3 times higher in PB B-cells and 4 times 
higher when analyzing by i-FISH in BM cells. These find-
ings suggest that all three methods should be used for 
full information concerning the genetic rearrangements 
both in BM cells and B-cells in B-CLL/SLL. Ambiguous are 
the findings of the normal karyotype in B-cells of PB while 
karyotype in BM cells was abnormal. Accumulation of the 
information about previously unidentified chromosomal 
rearrangements in relapse of the disease may help to un-
derstand the ways of resistance formation to chemotherapy. 
Mismatch in abnormal karyotypes in BM and PB B-cells 
by the presence of quantitative and structural chromosomal 
rearrangements may be indicative of simultaneous and 
independent processes of abnormal clone formation in the 
lymph nodes and BM hematopoietic cells.
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